Canine leishmaniosis, caused by Leishmania infantum, is a vector-borne disease. The immune response in infected dogs ...

Figure 1 Schematic diagram of NAb-mediated protective mechanisms against SARS-CoV-2 infection.(A) Neutralization mechanisms: Following the binding of NAbs (via Fab) to the RBD of the S1 subunit of ...

Objective To compare acute treatment responses and long-term outcome in leucine-rich glioma-inactivated 1 (LGI1) antibody encephalitis. Methods Retrospective case series of 118 patients with LGI1 ...

(UroToday.com) The 2025 ASCO annual meeting featured a urothelial carcinoma rapid oral abstract session and a presentation by Dr. Xinan Sheng discussing results from a phase 1b/2 study assessing ...

Among the patients with PD-L1 TPS<1%, IBI363 demonstrated outstanding efficacy signals: in the 1/1.5 mg/kg group (N=10), the confirmed ORR was 30.0% and the DCR was 90.0%, while that of the 3 mg ...

Iluzanebart’s failure is another ding for a TREM2 space that has already seen a recent high-profile failure. Last November, Alector’s TREM2 antibody failed its own Phase II study for Alzheimer’s ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B for the German biotech.

The initial data from the Phase I trial (NCT05652335) of JNJ-5322 shows that the trispecific antibody led to a 100% overall response rate (ORR) in 27 patients who were naïve to anti-BCMA/-GPRC5D ...

Novel high-throughput protein detection technologies are critically needed for population-based large-scale SARS-CoV-2 antibody detection as well as for monitoring quality and duration of immunity ...

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendritic cell neoplasm ...

In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus pembrolizumab resulted in durable responses with improved progression ...